GRIMES & Co WEALTH MANAGEMENT LLC Sells 11,604 Shares of Novo Nordisk A/S $NVO

GRIMES & Co WEALTH MANAGEMENT LLC reduced its position in shares of Novo Nordisk A/S (NYSE:NVO) by 9.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 113,752 shares of the company’s stock after selling 11,604 shares during the period. GRIMES & Co WEALTH MANAGEMENT LLC’s holdings in Novo Nordisk A/S were worth $6,312,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of NVO. Kingstone Capital Partners Texas LLC raised its holdings in shares of Novo Nordisk A/S by 301,443.6% during the 2nd quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company’s stock worth $690,560,000 after buying an additional 10,001,898 shares in the last quarter. SG Americas Securities LLC grew its position in Novo Nordisk A/S by 2,101.5% in the third quarter. SG Americas Securities LLC now owns 2,383,176 shares of the company’s stock valued at $132,242,000 after acquiring an additional 2,274,925 shares during the last quarter. Bank of Montreal Can raised its stake in Novo Nordisk A/S by 101.4% during the second quarter. Bank of Montreal Can now owns 2,475,300 shares of the company’s stock worth $170,845,000 after acquiring an additional 1,246,467 shares in the last quarter. DAVENPORT & Co LLC lifted its holdings in shares of Novo Nordisk A/S by 54.8% in the third quarter. DAVENPORT & Co LLC now owns 2,642,498 shares of the company’s stock worth $146,644,000 after acquiring an additional 935,468 shares during the last quarter. Finally, Sustainable Growth Advisers LP boosted its stake in shares of Novo Nordisk A/S by 11.7% in the 2nd quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company’s stock valued at $427,416,000 after purchasing an additional 649,390 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

NVO has been the subject of a number of research analyst reports. Hsbc Global Res cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 24th. BMO Capital Markets reiterated a “market perform” rating on shares of Novo Nordisk A/S in a report on Tuesday, December 23rd. Morgan Stanley reissued an “underweight” rating and set a $42.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, December 3rd. HSBC restated a “hold” rating and set a $54.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, December 10th. Finally, The Goldman Sachs Group dropped their target price on Novo Nordisk A/S from $60.00 to $54.00 and set a “buy” rating for the company in a research report on Friday, November 28th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, eleven have assigned a Hold rating and four have issued a Sell rating to the company. According to MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Hold” and an average price target of $56.21.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $59.83 on Tuesday. The company has a market capitalization of $267.12 billion, a price-to-earnings ratio of 17.39 and a beta of 0.66. The company has a quick ratio of 0.57, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a twelve month low of $43.08 and a twelve month high of $93.80. The stock has a fifty day simple moving average of $49.87 and a 200 day simple moving average of $55.15.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.25. The firm had revenue of $11.79 billion for the quarter, compared to analyst estimates of $11.98 billion. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%. Sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: U.S. oral Wegovy rollout broadens commercial reach: Novo has launched its oral GLP‑1 (the “Wegovy Pill”) across a wide pharmacy network, making it the first oral weight‑loss GLP‑1 widely available in the U.S.; that distribution scale supports faster adoption and incremental sales versus an injection‑only offering. Read More.
• Positive Sentiment: Management sees a bigger oral market long term: Novo executives now expect oral GLP‑1 pills to capture over one‑third of the GLP‑1 market by 2030, implying a larger addressable market and more diverse revenue mix than previously modeled. That raises longer‑term revenue potential and reduces single‑product concentration risk. Read More.
• Positive Sentiment: Behavioral/health spillovers bolster product narrative: Research linking GLP‑1 receptor agonists to lower household spending on alcohol and tobacco supports a broader public‑health and societal value story that can aid payer conversations and public acceptance. Read More.
• Neutral Sentiment: Unusual options activity signals trader interest but not direction: Elevated/options flows show speculative positioning or hedging ahead of catalysts (sales data, guidance, regulation); could increase volatility in the short term without indicating a definitive fundamental shift. Read More.
• Neutral Sentiment: Increased analyst and fund attention raises visibility: Coverage from Fundsmith, Zacks and healthcare ETF narratives is driving investor focus on NVO (both positive for liquidity and sentiment but mixed on valuation). Monitor earnings/sales prints and guidance for conviction. Read More.
• Negative Sentiment: Compounded GLP‑1s pose a near‑term demand and pricing risk: CEO Mike Doustdar warned up to ~1.5M U.S. patients may be using compounded (unapproved, cheaper) GLP‑1 alternatives — that substitution can blunt uptake of branded products and pressure pricing if regulators or payers don’t constrain the compounding market. Read More.
• Negative Sentiment: Analyst caution on valuation and execution: Several commentaries urge caution despite investor confidence — potential overextension in the stock, reliance on continued rapid adoption, and execution risk around pharmacy rollout and payer coverage could cap upside. Read More.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.